ArticleAging2024
Identification of metabolomic changes and potential therapeutic targets during ovarian aging.
Article in Aging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Molecular characteristics of follicular fluid in advanced maternal age women with different ovarian reserves: a multi-omics study.BMC women's health · 2026Article
- Cerebrospinal fluid metabolites and their association with female reproductive disorders: insights from mendelian randomization.Journal of ovarian research · 2026Article
- Integrated Network Toxicology and Metabolomics Reveal the Ovarian Toxicity Mechanisms of Chronic Carbofuran Exposure in Female Mice.International journal of molecular sciences · 2025Article
- Studying ovarian aging and its health impacts: modern tools and approaches.Genes & development · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo reveal the metabolic differences of follicle fluid (FF) and granulosa cell (GC) between younger women and advanced age women in ART cycles, and then find potential therapeutic targets of ovarian aging.
methodsForty-five patients were included in the study and they were divided into three groups according to their age (Group A: 20-30 years old; Group B: 30-35 years old; Group C: 35-45 years old). All patients underwent controlled ovarian stimulation using the follicular phase long-acting protocol, FF and GC were obtained 36-38 hours after HCG administration. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used for metabolomics analysis and metabolic pathway analysis (MetPA) was utilized to find related pathways.
resultsBetween group A and group C, there were 72 and 21 differential metabolites in FF and GC, respectively. KEGG enrichment analysis showed six pathways were co-enriched by the differential metabolites of FF and GC. Among them, we noticed that in the pathway GABAergic synapse, GABA (gamma-aminobutyric acid) was down-regulated in GC, while its downstream metabolite succinic acid was down-regulated in FF. Further ROC curve analysis was performed on these two metabolites, and the results showed that they all had a favorable predictive value.
conclusionThis study indicated that GABA and succinic acid could be potential therapeutic targets for ovarian aging, GABA may delay ovarian aging and improve ovarian function through its antioxidant properties, which may be a future direction of clinical treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.